Related Experiment Video
Updated: Sep 30, 2025

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
Oncological drug discovery: AI meets structure-based computational research
Marina Gorostiola González1, Antonius P A Janssen2, Adriaan P IJzerman3
1Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Abstract:
The integration of machine learning and structure-based methods has proven valuable in the past as a way to prioritize targets and compounds in early drug discovery. In oncological research, these methods can be highly beneficial in addressing the diversity of neoplastic diseases portrayed by the different hallmarks of cancer. Here, we review six use case scenarios for integrated computational methods, namely driver prediction, computational mutagenesis, (off)-target prediction, binding site prediction, virtual screening, and allosteric modulation analysis. We address the heterogeneity of integration approaches and individual methods, while acknowledging their current limitations and highlighting their potential to bring drugs for personalized oncological therapies to the market faster.
Insights
Machine learning and structure-based methods accelerate early drug discovery for cancer by predicting drivers, targets, and modulations. This integration aids in developing personalized oncological therapies more efficiently.
Area of Science:
- Computational biology
- Drug discovery
- Oncology
Background:
- Machine learning and structure-based computational methods are crucial for prioritizing drug targets and compounds.
- Neoplastic diseases present significant challenges due to their diverse nature, necessitating advanced research approaches.
Purpose of the Study:
- To review the application of integrated computational methods in oncological research.
- To explore six specific use-case scenarios for these integrated approaches.
- To highlight the potential of these methods in accelerating personalized cancer therapy development.
Main Methods:
- Review of integrated machine learning and structure-based computational methods.
- Analysis of six key use-case scenarios: driver prediction, computational mutagenesis, (off)-target prediction, binding site prediction, virtual screening, and allosteric modulation analysis.
- Discussion of integration approaches, individual method capabilities, and limitations.
Main Results:
- Integrated computational methods offer significant benefits in addressing the complexity of cancer.
- Six distinct use-case scenarios demonstrate the versatility of these approaches in drug discovery.
- The heterogeneity of integration strategies and methods is acknowledged, alongside their current constraints.
Conclusions:
- Integrated computational methods are vital for advancing oncological research and drug discovery.
- These approaches hold promise for overcoming limitations in current cancer therapy development.
- The potential exists to expedite the delivery of personalized cancer treatments to patients.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
07:46Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...